CIDP PBMC
About: CIDP PBMC samples are isolated from donors with clinically confirmed Chronic Inflammatory Demyelinating Polyneuropathy (CIPD). Ideal for studying autoimmune T and B cell responses, peripheral nerve inflammation, and mechanisms of demyelination.
| Lot # | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 73575 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 10M | Caucasian | 85 | Male |
IVig Q2W Eliquis 5 mg BID Metoprolol Zetia Crestor Tramadol PRN Furosemide Eliquis
|
1 | |||
| 73440 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 10M | Caucasian | 82 | Male |
Vitamins QD Amlodipine 5mg QD Gabapentin 300mg QD Losartan 50mg QD Xarelto 20mg QD
|
1 | |||
| 75281 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 10M | Caucasian | 85 | Male |
IVig Q3W Eliquis 5 mg BID Metoprolol QD Zetia QD Crestor QD Tramadol PRN Furosemide PRN
|
2 | |||
| 72939 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 10M | Caucasian | 69 | Male |
Vyndamax 61 mg QD
|
4 | |||
| 51866 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 5M | Caucasian | 60 | Female |
Synthroid 88 mcg QD IVIg 40 gm QD x 4 days Q6W Albuterol Inh PRN Potassium Chloride 20 mEq BID Pepcid 40 mg QD Nexium 40 mg QD Losartan 50 mg QD Advair Inh 1 puff BID HCTZ 25 mg QD Cellcept 1000 mg BID
|
4 | $891.00 | ||
| 52298 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 5M | Caucasian | 59 | Female | United States (US) |
IVIg QOW Fluticasone Nasal Spray Bupropion 150 mg QD Albuterol Inh PRN Fluoxetine 40 mg QD Pregabalin 100 mg Irbesartan 150 mg Simvastatin 10 mg Humalog Insulin Lantus Insulin Glucagon Ipratropium Nasal Spray Clonzepam
|
5 | $891.00 |
High-Quality CIDP PBMC for Research
CIDP PBMC products are sourced from donors clinically diagnosed with CIDP and processed under stringent conditions to support research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies on disease-specific immune dysregulation, T cell subsets, and cytokine production.
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed CIDP donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified CIDP diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional cidp-specific data available upon request
Applications
- Biomarker discovery and validation
- Drug screening and therapeutic development
- Immune pathway analysis in cidp pathophysiology
- Transcriptomic and proteomic profiling
Quality and Compliance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Shipping
CIDP PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – with the exception of GMP leukopaks, all our products are research use only (RUO).
1 Answer
Our complete catalog can be found here: https://sanguinebio.com/products/
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective colleciton services to tailored to fit your research. For more information and request a quote, please see: https://sanguinebio.com/prospective-biospecimen-collection-services/
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory which can be found here https://sanguinebio.com/products/?pro_inventory=inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: https://sanguinebio.com/quality-and-compliance/
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.